Spondyloarthropathy pathophysiology

Jump to navigation Jump to search

Pathophysiology

Spondyloarthropathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating spondyloarthropathies from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Spondyloarthropathy pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Spondyloarthropathy pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Spondyloarthropathy pathophysiology

CDC on Spondyloarthropathy pathophysiology

Spondyloarthropathy pathophysiology in the news

Blogs on Spondyloarthropathy pathophysiology

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Spondyloarthropathy pathophysiology

Spondyloarthropathies (SpA) is an inflammatory disease, which mainly affect the axial skeleton and peripheral joints same as other rheumatic disease but with different pathophysiology. there are two main processes that eventuate in symptoms of this disease:

  • Inflammation of bone marrow or entheses
    • This can cause pain and stiffness in affected joints
  • Ankylosis (overgrowth of the bone)
    • Eventuate in impaired function of the spine and reduction in range of motion of affected joints

Association of SpA with HLA-B27 gene have been known since 1973. In 95% of patients with Ankylosing spondylitis (AS) this allele is present, however, the reason why HLA-B27 is really strongly correlated to SpA is somehow uncleared.

There are some key points that can help to find the mechanism of SpA :

  • SpA does not display the prototypical genetic, clinical and immunological features of T-cell and/or B-cell- mediated autoimmune diseases.
  • B-cell and T-cell targeted therapies are not effective in SpA
  • HLA-B27-dependent UPR leads to augmented IL-23 production, but the role of UPR in vivo remains to be investigated in more detail.
  • Alternative macrophage polarization is a hallmark of SpA.
  • Innate immune cells rather than T cells are the main producers of IL-17 in SpA.

The genetic responsibility in SpA have been discussed and is concluded in numerous studies, albeit, by the advent of new technological devices, HLA-B27 subtypes are known better than before.

In the table below association of some genes and their association in the specific type of SpA are described

Overview of the gene, and their association in SpA
HLA-B27 subtype Association
HLA-B*2702 Association with AS
HLA-B*2704 Association with SpA
HLA-B*2705 Strong association with AS
HLA-B*2706 Very weak association with SpA
HLA-B*2709 AS sparing

Not only HLA-B gene are suspected for SpA, but also there are other genes that their association in presence of SpA are under investigation, which included:

  • HLA-B (Associated with Ankylosing spondylitis )
  • ERAP1 (Associated with Ankylosing spondylitis )
  • IL23R (Associated with Ankylosing spondylitis )
  • TNFRSF1A (Probably associated with Ankylosing spondylitis )
  • TRADD (Probably associated with Ankylosing spondylitis )
  • TNFRSF15 (Probably associated with Ankylosing spondylitis )
  • IL1A (Probably associated with Ankylosing spondylitis )
  • IL1R2 (Probably associated with Ankylosing spondylitis )
  • CARD9 (Probably associated with Ankylosing spondylitis )
  • ANTXR2 (Probably associated with Ankylosing spondylitis )